Alimera reports Iluvien sales growth

Alimera Sciences, Inc., reported revenue for the first quarter of 2014 of $2.1 million compared to $935,000 in the fourth quarter of 2013. The company did not report any revenue for the first quarter of 2013.

"We achieved solid revenue growth from sales of Iluvien during this first quarter of 2014 due to increasing demand for Iluvien in Germany and the early implementation of NICE guidance for the reimbursement of Iluvien in the United Kingdom," said Dan Myers, president and chief executive officer of Alimera Sciences. "We are continuing our plans for the geographic expansion of Iluvien through our pursuit of a public price in France, our ongoing application for 10 additional European Union country approvals through the Mutual Recognition Procedure, a recently secured reimbursement in Portugal and our partnership with Specialised Therapeutics Australia for the distribution of Iluvien in Australia and New Zealand."

Alimera initiated the commercial launch of Iluvien (fluocinolone acetonide 190 micrograms intrvitreal implant in applicator) to treat vision impairment associated with chronic diabetic macular edema in Germany and the United Kingdom during the second quarter of 2013 and began recognizing the cost of goods sold at that time.